Frezoulis Petros S, Harper Aaron, Mason Sarah L
Southfields Veterinary Specialists, Laindon, Essex, UK.
Wear Referrals, Bradbury, County Durham, UK.
J Feline Med Surg. 2022 Dec;24(12):1212-1218. doi: 10.1177/1098612X211070737. Epub 2022 Feb 7.
Radiation therapy is the treatment of choice for cats with sinonasal carcinomas. Different protocols have been described in the literature, though a clear consensus regarding the optimal protocol is lacking. The aim of the study was to describe the tolerability, efficacy and outcome of cats treated with a cyclical hypofractionated protocol.
Cats with histologically diagnosed sinonasal carcinomas in a single institution were retrospectively included. All patients were treated with a cyclical hypofractionated protocol ('QUAD shot' regime). Cats were treated with 4 Gray (Gy) delivered in four fractions within 48 h, with a minimum of 6 h between two treatments, and repeated every 3-4 weeks for a total dose of 48 Gy in three cycles.
Seven cats met the inclusion criteria. Nasal discharge and sneezing were the most common presenting complaints. All cats presented with advanced stage of disease with CT examination (three with modified Adams stage 3 and four with stage 4). Clinical improvement was seen in six cats. Five cats had a follow-up CT; one had a complete response, two had partial responses, one had stable disease and one had progressive disease. Two cats were still alive at the time of writing while four were euthanased owing to tumour-related causes. The median overall survival time was 460 days. The 1-year survival time was 80% and the 2-year survival time was 0%. Severe acute or late toxicity was not reported.
This is the first report of a cyclical hypofractionated protocol in the veterinary literature that can provide prolonged survival in cats with advanced stage sinonasal carcinoma. Its use should be considered in patients when prolonged hospitalisation can be detrimental to quality of life, while still delivering a therapeutic total dose of radiation therapy.
放射治疗是鼻窦癌猫的首选治疗方法。文献中描述了不同的方案,但对于最佳方案缺乏明确的共识。本研究的目的是描述采用周期性大分割方案治疗的猫的耐受性、疗效和结局。
回顾性纳入在单一机构中经组织学诊断为鼻窦癌的猫。所有患者均采用周期性大分割方案(“四联注射”方案)治疗。猫在48小时内分4次给予4格雷(Gy),两次治疗之间至少间隔6小时,每3 - 4周重复一次,三个周期的总剂量为48 Gy。
7只猫符合纳入标准。鼻分泌物增多和打喷嚏是最常见的就诊主诉。所有猫经CT检查均表现为疾病晚期(3只处于改良亚当斯3期,4只处于4期)。6只猫有临床改善。5只猫进行了随访CT检查;1只完全缓解,2只部分缓解,1只病情稳定,1只病情进展。撰写本文时,2只猫仍存活,4只因肿瘤相关原因实施了安乐死。中位总生存时间为460天。1年生存率为80%,2年生存率为0%。未报告严重的急性或晚期毒性反应。
这是兽医文献中关于周期性大分割方案的首次报告,该方案可为晚期鼻窦癌猫提供延长生存期的效果。当长期住院可能对生活质量有害,同时仍能给予治疗性放疗总剂量时,应考虑在患者中使用该方案。